CBD Life Sciences (CBDL) Stock Price, News & Analysis

Company Overview

CBD Life Sciences, Inc. is a U.S.-based company focused on developing and commercializing cannabinoid‐enhanced products for the wellness and consumer healthcare markets. The company’s core strategy centers on leveraging plant-derived phytocannabinoids, along with complementary natural ingredients, to formulate a range of topical and ingestible offerings. CBD Life Sciences operates under an emerging‐brand model, seeking to position its products at the intersection of pharmaceutical‐grade quality and mainstream consumer appeal.

The company’s product portfolio includes broad‐spectrum hemp-derived topical creams, gels and balms designed for localized relief, as well as oral formulations such as capsules, tinctures and soft gels aimed at general wellness support. Many of these products incorporate proprietary formulations and delivery systems intended to enhance bioavailability and absorption. CBD Life Sciences emphasizes rigorous quality control, sourcing non-GMO, pesticide-free hemp and subjecting finished goods to third‐party laboratory testing for potency, purity and compliance with federal guidelines.

CBD Life Sciences markets its products through multiple channels, including direct-to-consumer e-commerce platforms, retail partnerships and select distribution agreements across North America. The company has pursued strategic alliances with contract manufacturers and fulfillment providers to scale production capacity and streamline logistics. While still in its early commercial stages, CBD Life Sciences is positioning itself to capitalize on growing consumer interest in plant-based wellness solutions.

Leadership at CBD Life Sciences comprises professionals with backgrounds in nutraceutical development, pharmaceutical manufacturing and consumer packaged goods. This management team oversees research and development efforts, regulatory compliance initiatives and brand-building activities. As regulatory frameworks for hemp-derived cannabinoids continue to evolve, the company remains focused on innovation, quality assurance and expanding its retail footprint.

Key Stats

• Today's Range: $0.0002 to $0.0003
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0010
• Volume: 1.14 million shs
• Average Volume: 20.09 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CBDL
• CIK: 1776073
• Web: www.optiumcyber.com
• Phone: (480) 410-6780
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A